These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 12377195)
1. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Pan PY; Zang Y; Weber K; Meseck ML; Chen SH Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195 [TBL] [Abstract][Full Text] [Related]
2. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445 [TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
4. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826 [TBL] [Abstract][Full Text] [Related]
5. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. Pan PY; Gu P; Li Q; Xu D; Weber K; Chen SH J Immunol; 2004 Apr; 172(8):4779-89. PubMed ID: 15067054 [TBL] [Abstract][Full Text] [Related]
6. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal. Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303 [TBL] [Abstract][Full Text] [Related]
7. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460 [TBL] [Abstract][Full Text] [Related]
13. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348 [TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709 [TBL] [Abstract][Full Text] [Related]
15. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855 [TBL] [Abstract][Full Text] [Related]
16. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166 [TBL] [Abstract][Full Text] [Related]
17. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. May KF; Chen L; Zheng P; Liu Y Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989 [TBL] [Abstract][Full Text] [Related]